Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS will host a webcast on July 14, 2020, at 10am ET to discuss the significant impact of vaginal yeast infections, with a focus on their innovative drug candidate, ibrexafungerp. This event follows positive top-line results from two Phase 3 trials for vulvovaginal candidiasis (VVC), with a planned NDA submission in the latter half of 2020. Key opinion leaders will address the existing treatment gaps and the commercial potential of ibrexafungerp in the VVC market, underscoring SCYNEXIS's commitment to advancing solutions in women's health.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced a presentation at the BIO Digital International Convention from June 8-12, 2020. CEO Marco Taglietti will discuss the company's progress towards becoming a fully integrated commercial entity, targeting the treatment of vaginal yeast infections. The presentation will highlight the positive Phase 3 VANISH program for oral ibrexafungerp, with an NDA submission expected in mid-2021. SCYNEXIS focuses on developing innovative antifungal therapies to combat drug-resistant infections, leveraging expertise in anti-infective drug development.
SCYNEXIS, Inc. (NASDAQ: SCYX) has appointed Jim Maffezzoli as the new Vice President of Marketing and Sales, effective June 1, 2020. Maffezzoli brings almost 20 years of experience in women’s health marketing and will oversee the commercialization of ibrexafungerp, an investigational treatment for vaginal yeast infections.
With an NDA submission for ibrexafungerp anticipated in the second half of 2020, this strategic appointment aims to enhance the company’s marketing efforts in women's health, addressing a significant unmet need in the treatment landscape.
SCYNEXIS announced positive results from the Phase 3 VANISH-306 study for oral ibrexafungerp, aimed at treating vaginal yeast infections, with an NDA submission expected in H2 2020. Concurrently, enrollment continues in the Phase 3 CANDLE study for recurrent infections. The company also reported positive interim results from the Phase 3 FURI study for severe fungal infections, showing an 83% clinical benefit in 41 patients. Financially, SCYNEXIS strengthened its position with $10 million in convertible notes and a $20 million stock purchase agreement, ensuring a cash runway into mid-2021.